Table of Contents
SAN FRANCISCO ─ Hims & Hers Health, Inc. has introduced a new GLP-1 Supply Tracker to help address rising issues with accessing GLP-1 medications, commonly prescribed for weight management. Since September, nearly 80,000 people on the Hims & Hers platform have reported difficulties in obtaining branded GLP-1 drugs, especially in states with higher obesity rates, such as Texas, where close to 5,000 users have shared their access challenges. The tracker, drawing nearly 7,000 user entries in just a week, allows individuals to report their experiences, highlighting areas where supply is lacking.
Hims & Hers encourages individuals experiencing challenges obtaining their prescribed medications to use the GLP-1 Supply Tracker to report their experiences and contribute to advocacy efforts. Through this initiative, the company aims to bridge the gap in GLP-1 availability, helping more people access the necessary health solutions.
CEO Andrew Dudum emphasized the company’s commitment to understanding and addressing these healthcare access issues. He noted the importance of using the Hims & Hers platform to advocate for improved availability and communicate these supply challenges to state and federal agencies. The platform’s insights show a significant gap between demand and supply, with nearly 30% of weight loss customers unable to fill their prescriptions due to limited pharmacy availability. The company’s proactive approach aims to bring greater awareness to the issue and support patients facing barriers to treatment access.
In addition to gathering consumer feedback, Hims & Hers is also engaging with policymakers to bring the supply issues to their attention to improve access to these medications. According to research from the University of Southern California, demand for semaglutide, a popular GLP-1 drug, surged by 442% between January 2021 and December 2023, partly due to a reduction in the stigma associated with obesity treatment.
